Research view
Groups that published on this disease or run trials on it, from public registries and publications. Researchers appear by name only once their profile is published.
One card per institution. Filter by target, by country, or show only institutions in EU-13 (Horizon Europe widening) countries.
EU-13 is a filter, not a ranking: it only narrows the list.
The University of Texas MD Anderson Cancer Center · Houston, United States
Team details appear once the team leader joins.
Is this your team? Claim it
Latest publication · J Immunother Cancer, Dec 2025Patterns of immune-related adverse events and treatment responses in adolescents and young adults with melanoma during initial and rechallenge immune checkpoint inhibitor therapy.
Memorial Sloan Kettering Cancer Center · New York, United States
Team details appear once the team leader joins.
Is this your team? Claim it
Latest publication · Histopathology, Jan 2026Analysis of SCLC subtype markers (ASCL1, NEUROD1, POU2F3, YAP1), DLL3, OTP, and TTF1 in 300 lung carcinoids and enteropancreatic neuroendocrine tumours.
Rozzano, Italy
University of Pennsylvania · Philadelphia, United States
Team details appear once the team leader joins.
Is this your team? Claim it
Latest publication · Proc Natl Acad Sci U S A, Dec 2025Dual-targeted ping-pong CAR T cells: Leveraging peripheral expansion to improve solid tumor immunotherapy.
Tampa, United States
Madrid, Spain
Dallas, United States
Atlanta, United States
Salt Lake City, United States
Columbus, United States
Lyon, France
Madrid, Spain
New Haven, United States
Barcelona, Spain
Portland, United States
Los Angeles, United States
Villejuif, France
New York, United States
Columbus, United States
Buffalo, United States
Nashville, United States
São Paulo, Brazil
Evanston, United States
23 of 23+ institutions, ordered by recent publications and open trials. This is not a ranking of quality.
Terminated, withdrawn and suspended trials with the reason the sponsor gave in the registry, quoted word for word.
Terminated
Surufatinib in Combination With Tislelizumab in Subjects With Advanced Solid Tumors
“Study terminated by sponsor”Registry text, quoted unchanged. SourceWithdrawn
“Study never started/ will not proceed.”Registry text, quoted unchanged. SourceTrials whose registry record says individual participant data (IPD) will be shared.
Find publications on this disease by a MeSH method term, for example a sequencing or imaging method.
See which targets of this disease your abstract mentions, and go to the people working on them.
Matched in your browser only. The text is not sent, saved or logged.
Sources: ClinicalTrials.gov, EU CTR, OpenAlex, PubMed. Machine-matched links are labelled.